- Improving time to diagnosis, diagnostic workup, and recognition of clinical signs suggestive of PID
- Reviewing the impact of and exploring strategies to optimize treatment adherence
- Examining health disparities experienced by PID patients, including impact of race and ethnicity on disease management and challenges faced by patients living in rural areas
- Promoting patient-centered approaches to care, including shared-decision making and supporting patient understanding of treatment options
Independent Medical Education Grants
Independent Medical Education Grants
Takeda and its Alliance partners are committed to supporting high-quality, un-biased, evidence-based independent medical education for healthcare professionals, teams, patients, payers and systems designed to:
- Improve knowledge, enhance skills, and support behavior change
- Close clinical and practice gaps
- Improve the quality and delivery of patient care
- Enable patients to take an active role in their healthcare
Independent Medical Education is defined as education that is evidence-based, fair-balanced, unbiased, planned and implemented independent of industry influence, free of bias and not influenced by Takeda or its Alliance partners.
Educational Areas of Interest
Below are areas of interest for independent medical education support by US Medical Affairs. If you have questions about an area not listed, please contact: [email protected]
Dermatology
- Understanding the medical need/criteria for transitioning a patient from topical to systemic therapies
- Reviewing the mechanism of disease of PSO including the role of tyrosine kinase 2
- Reviewing available and emerging therapies, and their place in the treatment landscape for patients with moderate-to-severe PSO
- Psoriatic Arthritis (PSA)
Gastroenterology
- Improving recognition and differential diagnosis of IBD earlier in the disease course
- Reviewing available and emerging therapies, and their place in the treatment landscape
- Implementing treatment changes, including initiation of advanced therapy at the appropriate time, to enable patients to achieve remission and avoid complications
- Using risk stratification, clinical factors, and patient factors including social determinants of health to make evidence-based treatment decisions
- Determining individualized treatment selection and sequencing to prevent disease progression and to manage IBD long-term
- Recognizing and addressing care disparities and barriers to equitable care of patients with IBD
- Providing culturally competent care that facilitates shared decision-making and encourages alignment of disease perception and treatment goals between patients and HCPs
- Exploring EoE pathophysiology, disease course and disease severity to inform episodic and chronic management approaches
- Applying current guidelines for the diagnosis and classification of EoE to reduce diagnostic delays
- Reviewing data regarding safety, efficacy, and mechanisms of action of available and emerging options for episodic and chronic management of EoE
- Facilitating evidence-based, personalized, and equitable care of diverse patients with EoE by a multidisciplinary team in the community setting
- Optimizing transition of care from pediatric to adult management
- Examining potential impacts of treatment modalities and approaches on healthcare costs and utilization, with consideration of economic impact on patients
- Improving recognition and diagnosis of SBS-IF, including psychosocial impacts
- Reviewing clinical data and real-world evidence regarding safety, efficacy, and mechanisms of action for available and emerging treatments
- Determining optimal management strategies for SBS-IF in children and adults and implementing those strategies in the community care setting
- Optimizing multidisciplinary care of children and adults with SBS-IF throughout the disease course
- Irritable Bowel Syndrome (IBS)
- Chronic Idiopathic Constipation (CIC)
- Crohn’s Perianal Fistulas (CPF)
- Fellowships except in response to a specific Call for Grant Applications (CGA). CGA postings can be found by following this link: https://tsupportportal.com/CGA/index.html
Hematology
- Understanding the importance of multimeric profile in the treatment of VWD
- Clinical impact of replacement therapy with VWF interaction with endogenous FVIII levels
- Addressing the consequences of inadequate or suboptimal care
- Impact of prophylaxis in the VWD population
- Treating according to clinical severity
- Reviewing the existing therapeutic approaches available for VWD management including benefits and limitations
- Identifying the challenges faced in the treatment of VWD, exploring innovative strategies for improved patient care through tailored treatment plans, ideal ways to monitor patients in clinical practice
Immunology
- Highlighting the CIDP patient journey including burden of illness, diagnostic delay and guideline approaches for differential diagnosis
- Enhancing adherence to treatment guidelines for induction and maintenance treatment of CIDP
- Evaluating safety, efficacy, and administration of treatment options for patients with CIDP and considerations for clinical decision making
- Addressing health equity and healthcare disparities in the neuromuscular disease community
- Reinforcing long-term efficacy, safety, and QOL improvements for reducing HAE burden of disease
- Exploring the importance of tailoring care in adult and pediatric patients, including treatment and prophylaxis as well as transitions of care
- Examining social determinants of health (SDOH) faced by patients with HAE and the impact on disease management and outcomes
- Understanding the unique challenges faced by patients living in rural areas and effective strategies to manage HAE in these populations
- Alpha-1 Antitrypsin Deficiency (AATD) focused on lung disease
- Immune-mediated inflammatory conditions other than CIDP and PID
- Multifocal motor neuropathy or neuromuscular disorders other than CIDP
- Secondary immunodeficiency disorders
- Systemic Lupus Erythematosus (SLE)
Neuroscience
- Understanding the differences in the efficacy and safety profiles among classes of antidepressants
- Implementing shared decision-making and patient-centered treatment planning, treating to remission, and educating patients on the potential for achieving remission
- Evaluating for treatment adherence, residual symptoms, tolerability issues, and overall patient well being
- Determining when and how to switch antidepressants or adjust treatment to achieve symptomatic and functional improvements
- Promoting strategies to achieve effective shared decision-making between healthcare providers and patients
- Adopting measurement-based care and/or patient reported outcomes when evaluating the extent of patient issues and making treatment decisions
- Highlighting the importance and effectiveness of a collaborative care model when managing patients with MDD
- Improving patient access, health equity and supportive networks amongst all patients
- Appreciating the burden of illness of patients with NT1 suffering from symptoms of excessive daytime sleepiness and cataplexy
- Improving the diagnosis of narcolepsy and the ability to differentiate between narcolepsy types
- Understanding the role of orexin in sleep-wake regulation and pathophysiology of narcolepsy
- Evaluating the current and emerging clinical landscape of narcolepsy
- Alzheimer Disease
- Attention-deficit/hyperactivity disorder
- Central Disorders of Hypersomnolence other than NT1
- Developmental and Epileptic Encephalopathy, Adult Epilepsy, or Pediatric Epilepsy
- Huntington Disease
- Parkinson Disease
Rare Metabolic Diseases
- Emphasizing the importance of newborn screening initiatives and biomarkers to enable early diagnosis
- Evaluating the safety and efficacy of available treatments
- Addressing challenges in Women’s Health in Gaucher Disease and strategies to support personalized care
- Identifying the drivers of bone disease in Gaucher patients and its impact on treatment outcomes
- Improving patient outcomes through newborn screening and strategies to support implementation of NBS
- Optimizing disease management strategies to support personalized care for individuals
- Identifying the challenges faced by patients with Hunter Syndrome and their caregivers
- Metachromatic Leukodystrophy (MLD)
- Fabry Disease
- Stem Cell Transplant
Transplant
- Understanding the burden of illness and unmet needs of inadequately treated CMVi among transplant recipients
- Identifying risk factors and mitigation strategies for CMVi reactivation and inadequately CMVi
- Highlighting the importance of early identification and monitoring of high-risk post-transplant patients for timeline treatment intervention/s
- Addressing challenges in managing tolerability or adverse effects of anti-viral treatments for CMVi
- Identifying barriers and unmet treatment needs for post-transplant recipients with CMVi, including treatment intolerance and inadequately treated, refractory or drug-resistant CMVi
- Evaluating safety, efficacy and impact of modern treatment strategies for CMVi
Vaccines
- Dengue
Please visit Takeda Support for additional information on submitting medical education grant requests.
If you have any questions regarding Takeda’s medical education grants, please contact [email protected].